Hotstart Taq DNA Polymerase

  • Applications: PCR, qPCR
Need help with your order?
Find out more about placing an order here or contact us for technical support.
Pricing is for US customers only. For international pricing, please contact your local distributor. View Distributors Here.

Product Description

BioChain’s HotStart Taq Polymerase combines high specificity, sensitivity, and minimal optimization with a fast 10-minute activation time. During PCR reaction setup, DNA polymerases commonly exhibit some synthesis activity which can lead to amplification of mis-primed sequences and accumulation of primer-dimers that compromise the specificity and yield of the reaction. Non-specific amplification can be minimized with HotStart Taq Polymerase. Our ready-to-use HotStart Taq Polymerase is chemically modified causing its activity to be blocked at lower temperatures. Activity is restored when the enzyme is heated to 95oC during the initial denaturing process, enabling hot-start PCR. BioChain’s Hot-Start Taq Polymerase is a powerful, yet cost effective way to minimize pre-cycling polymerase activity for more efficient, specific PCR.
Looking for multiple donors or additional samples?

Product Specifications

Features Specifications
Size 250 units
Shipping Ambient Temperature
Sex Contact Us
Age At Sampling Contact Us
Enzyme Type Polymerase
Reagent Type Enzyme
Applications PCR, qPCR
CATALOG #: L7052250

Certificate of Analysis

Targeted Next Generation Sequencing (NGS), using Thermo Fisher’s Ion AmpliSeq panel, was performed to identify mutations and mutational hotspots in 35 well-characterized genes that are associated with oncology. These tissues are ideal for verification, genotyping, or identification of new mutational hotspots. Tissues found to not contain any mutational hotspots in a gene of interest may also be considered to be used as a negative control for assay performance.

The advantage of using BioChain’s CancerSeq AMS real tumor tissue versus genetically engineered tumor cell lines is that the tissues are far more representative of real clinical disease. Cancer cell lines or genetically altered cell lines have been used widely for in vitro tumor models, but these possess only a small proportion of the genetic variances seen in tumor tissues. Actual tumors generally carry multiple mutations instead of just one or two. Numerous studies have pointed out the striking genetic differences between cell lines and tumor samples by comparing microarrays, copy number changes, mutations, and mRNA expression profiles. We offer CancerSeq AMS pre-screened tissue as mounted sections or curls.

Please inquire for other options, such as whole block or extracted nucleic acids. The list of targeted genes is also included in each product’s data sheet


• Isolation of DNA with specific mutation profiles
• Validation of cancer marker mutation related drug candidates
• Companion diagnostic assay development
• Suitable for both IHC and in-situ hybridization assays
• Controls or verification for genotyping
• Cellular localization of tissue specific mRNA and protein expression

Advantages and Features:

• Deep sequencing by NGS with high coverage
• FFPE curls or slides available (inquire for blocks)
• Documentation of the tissue donor’s clinical histories is available
• Information regarding tumor type is available
• Complete NGS sequencing data available

Quality Data:

BioChain’s CancerSeq AMS pre-screened tissues come with detailed information regarding donor and cancer type, as well as NGS information such as chromosomal position, variant type (SNP or indel), alternate allele variations, quality score, depth of coverage, allele type, gene ID and more.